KR20170137113A - C형 간염 바이러스 중합효소의 저해제 - Google Patents

C형 간염 바이러스 중합효소의 저해제 Download PDF

Info

Publication number
KR20170137113A
KR20170137113A KR1020177030184A KR20177030184A KR20170137113A KR 20170137113 A KR20170137113 A KR 20170137113A KR 1020177030184 A KR1020177030184 A KR 1020177030184A KR 20177030184 A KR20177030184 A KR 20177030184A KR 20170137113 A KR20170137113 A KR 20170137113A
Authority
KR
South Korea
Prior art keywords
ethoxy
hcv
inhibitor
mmol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020177030184A
Other languages
English (en)
Korean (ko)
Inventor
이리나 씨. 제이콥슨
마이클 디. 피세
샘 에스. 이
Original Assignee
코크리스탈 파마, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코크리스탈 파마, 아이엔씨. filed Critical 코크리스탈 파마, 아이엔씨.
Publication of KR20170137113A publication Critical patent/KR20170137113A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
KR1020177030184A 2015-03-23 2016-03-23 C형 간염 바이러스 중합효소의 저해제 Abandoned KR20170137113A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562136857P 2015-03-23 2015-03-23
US62/136,857 2015-03-23
PCT/US2016/023664 WO2016154241A1 (en) 2015-03-23 2016-03-23 Inhibitors of hepatitis c virus polymerase

Publications (1)

Publication Number Publication Date
KR20170137113A true KR20170137113A (ko) 2017-12-12

Family

ID=55759915

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177030184A Abandoned KR20170137113A (ko) 2015-03-23 2016-03-23 C형 간염 바이러스 중합효소의 저해제

Country Status (18)

Country Link
US (2) US10464914B2 (https=)
EP (1) EP3274340B1 (https=)
JP (1) JP6741747B2 (https=)
KR (1) KR20170137113A (https=)
CN (1) CN107567442B (https=)
AU (1) AU2016235246B2 (https=)
CA (1) CA2979555C (https=)
DK (1) DK3274340T3 (https=)
EA (1) EA033622B1 (https=)
ES (1) ES2748974T3 (https=)
IL (1) IL254243B (https=)
MX (1) MX379015B (https=)
NZ (1) NZ735093A (https=)
PH (1) PH12017501687A1 (https=)
PL (1) PL3274340T3 (https=)
SG (1) SG11201707527YA (https=)
TW (1) TWI731854B (https=)
WO (1) WO2016154241A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI731854B (zh) * 2015-03-23 2021-07-01 美商共結晶製藥公司 C型肝炎病毒聚合酶之抑制劑
KR20210018806A (ko) * 2018-05-09 2021-02-18 코크리스탈 파마, 아이엔씨. Hcv의 치료를 위한 병용 요법
CN112745216A (zh) * 2019-10-30 2021-05-04 常州锐博生物科技有限公司 一种4-溴甲基苯甲酸甲酯及其衍生物的制备方法
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN114181187A (zh) * 2021-11-24 2022-03-15 上海应用技术大学 一种4-甲磺酰胺基丁酰胺化合物的制备方法
CN116283512B (zh) * 2023-02-24 2025-04-25 博诺康源(北京)药业科技有限公司 一种合成维兰特罗及其盐的方法
WO2025111414A1 (en) * 2023-11-21 2025-05-30 Katholieke Universiteit Leuven Trpm3-modulating benzofuran derivatives
CN119350612B (zh) * 2024-12-24 2025-10-24 浙江爱索拓标记医药科技有限公司 一种放射性同位素碳-14标记聚乙二醇单甲醚的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029075A1 (en) 1995-03-20 1996-09-26 Eli Lilly And Company 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
WO2002100846A1 (en) 2001-06-11 2002-12-19 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
US6881741B2 (en) 2001-06-11 2005-04-19 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
DE60221627D1 (de) 2001-12-21 2007-09-20 Virochem Pharma Inc Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
EA009943B1 (ru) * 2002-11-01 2008-04-28 Вирофарма Инкорпорейтед Соединения бензофурана, композиции и способы лечения и профилактики инфекций, вызванных вирусом гепатита с, и связанных с ним заболеваний
KR101058696B1 (ko) 2002-12-10 2011-08-22 바이로켐 파마 인코포레이티드 후라비바이러스 감염의 치료 또는 예방을 위한 화합물과방법
US20040192707A1 (en) 2002-12-10 2004-09-30 Laval Chan Chun Kong Compounds and methods for the treatment or prevention of Flavivirus infections
MXPA05006196A (es) 2002-12-10 2006-01-27 Virochem Pharma Inc Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus.
US20070293484A1 (en) 2004-05-20 2007-12-20 Sugen, Inc. Thiophene Heteroaryl Amines
DE102004061746A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
WO2006119646A1 (en) 2005-05-13 2006-11-16 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
PE20070814A1 (es) 2005-12-22 2007-08-16 Smithkline Beecham Corp Compuestos derivados de 2-carboxitiofeno como inhibidores de la polimerasa del virus de la hepatitis c (hcv)
WO2008017688A1 (en) 2006-08-11 2008-02-14 Smithkline Beecham Corporation 2-carboxy thiophene derivatives as anti-viral agents
TW200815384A (en) 2006-08-25 2008-04-01 Viropharma Inc Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein
WO2008043791A2 (en) 2006-10-13 2008-04-17 Smithkline Beecham Corporation Thiophene derivatives for treating hepatitis c
JP5290186B2 (ja) 2006-11-15 2013-09-18 ヴァイロケム ファーマ インコーポレイテッド フラビウイルス感染症の治療または予防用のチオフェン類似体
US20090274655A1 (en) 2006-11-17 2009-11-05 Richard Martin Grimes 2-carboxy thiophene derivatives as anti viral agents
GB0707092D0 (en) 2007-04-12 2007-05-23 Smithkline Beecham Corp Compounds
GB0712393D0 (en) 2007-06-26 2007-08-01 Smithkline Beecham Corp Compounds
GB0718435D0 (en) * 2007-09-21 2007-10-31 Northern Health And Social Car Wpund care formulation
ATE539070T1 (de) 2008-02-14 2012-01-15 Hoffmann La Roche Heterozyklische antivirale verbindungen
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
TW201136919A (en) * 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
AR082453A1 (es) * 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
AU2011329485A1 (en) * 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
US8771665B2 (en) 2010-12-17 2014-07-08 Cocrystal Discovery, Inc. Inhibitors of hepatitis C virus polymerase
WO2014055142A1 (en) 2012-06-20 2014-04-10 Cocrystal Discovery, Inc. Inhibitors of hepatitis c virus polymerase
TWI731854B (zh) * 2015-03-23 2021-07-01 美商共結晶製藥公司 C型肝炎病毒聚合酶之抑制劑

Also Published As

Publication number Publication date
SG11201707527YA (en) 2017-10-30
PL3274340T3 (pl) 2020-01-31
CA2979555A1 (en) 2016-09-29
DK3274340T3 (da) 2019-10-07
IL254243B (en) 2020-10-29
HK1243703A1 (zh) 2018-07-20
CN107567442A (zh) 2018-01-09
EA033622B1 (ru) 2019-11-11
US20200255393A1 (en) 2020-08-13
CA2979555C (en) 2023-12-19
CN107567442B (zh) 2021-05-25
EP3274340B1 (en) 2019-07-17
IL254243A0 (en) 2017-10-31
EA201792094A1 (ru) 2018-03-30
US10464914B2 (en) 2019-11-05
EP3274340A1 (en) 2018-01-31
US20180050998A1 (en) 2018-02-22
MX2017012238A (es) 2018-02-15
US10947210B2 (en) 2021-03-16
JP2018512453A (ja) 2018-05-17
ES2748974T3 (es) 2020-03-18
AU2016235246A1 (en) 2017-09-21
JP6741747B2 (ja) 2020-08-19
HK1249514A1 (en) 2018-11-02
AU2016235246B2 (en) 2020-12-10
NZ735093A (en) 2022-09-30
TWI731854B (zh) 2021-07-01
PH12017501687A1 (en) 2018-03-19
TW201643147A (zh) 2016-12-16
BR112017020168A2 (pt) 2018-06-05
MX379015B (es) 2025-03-10
WO2016154241A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
US10947210B2 (en) Inhibitors of Hepatitis C virus polymerase
US11629125B2 (en) Elimination of hepatitis b virus with antiviral agents
TWI519515B (zh) B型肝炎抗病毒劑
JP6495822B2 (ja) Hcv感染用の2’−クロロヌクレオシド類似体
US8771665B2 (en) Inhibitors of hepatitis C virus polymerase
US20120202794A1 (en) Compounds
US10426762B2 (en) Inhibitors of hepatitis C virus polymerase
HK1249514B (en) Inhibitors of hepatitis c virus polymerase
WO2013139206A1 (zh) 3-氧代-3,4-二氢-2-吡嗪甲酰氨类衍生物、其药物组合物、其制备方法及用途
BR112017020168B1 (pt) Compostos inibidores de polimerase para o vírus da hepatite c, usos dos mesmos, bem como combinação
HK1243703B (zh) C型肝炎病毒聚合酶的抑制剂
EA041357B1 (ru) Противовирусные соединения для элиминации вируса гепатита b

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PC1904 Unpaid initial registration fee

St.27 status event code: A-2-2-U10-U14-oth-PC1904

St.27 status event code: N-2-6-B10-B12-nap-PC1904